MedTrace Logo

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

NCT06563375 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-03-12

No results posted yet for this study

Summary

To evaluate the safety and preliminary efficacy of NP-101 in patients with solid tumors.

Conditions

Interventions

DRUG

NP-101

Given by mouth

Sponsors & Collaborators

  • Novatek Pharmaceuticals, Inc.

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Aung Naing, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-05
Primary Completion
2028-09-01
Completion
2030-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06563375 on ClinicalTrials.gov